Aim: Central pulse pressure and measures of arterial stiffness (augmentation index (AIx) and aortic pulse wave velocity (PWV)) predict morbidity and mortality in patients with stage 2 − 4 chronic kidney disease (CKD). Although statin therapy may be of vascular benefit in patients with CKD, the long-term effect of statins on central pulse pressure and arterial stiffness has not been assessed in this patient population. Hence, the aim of this study was to assess the long-term effects of atorvastatin on arterial stiffness and central blood pressure in patients with CKD. 
Introduction
Vascular disease, characterised by premature atherosclerosis and large artery stiffness, is a feature of Data assessing the relationship between arterial stiffness and the progression of CKD suggest that arterial stiffness becomes abnormal in stage 3 CKD and deteriorates as CKD progresses [6] [7] [8] [9] [10] [11] . In particular, Shinohara et al. found a steady increase in aortic PWV from 8.4 2.0 m/sec in stages 1 − 2 CKD, 10.1 2.3 m/sec in stages 3 − 4 CKD and 11.8 3.3 m/sec in stage 5 CKD 12) . This pattern is consistent with the known progression of cardiovascular disease that occurs with the progression of CKD; however, to our knowledge, there are no long-term prospective randomised controlled trials investigating the effects of interventions such as statin therapy on arterial stiffness in CKD patients.
Intervention studies with statins in hypercholesterolemic patients, without CKD, treated over oneyear have shown improved carotid artery stiffness 13) . In patients with rheumatoid arthritis, ezetimibe and simvastatin reduced aortic PWV and improved endothelial function 13) . The recently published CAFE-LLA study found that 10 mg per day atorvastatin did not alter central aortic blood pressure or hemodynamics in hypertensive patients from the ASCOT trial 14) . Clinical intervention studies with atorvastatin in CKD patients have been small, of short duration, and have only assessed endothelial function using brachial forearm flow mediated dilatation 15, 16) . In one small study in advanced CKD and dialysis patients, atorvastatin improved small artery stiffness over six weeks 17) . Whether intervention with statins can affect the progression of large arterial stiffness in the CKD population has not been assessed. The LORD Trial was designed to assess the effects of atorvastatin on the progression of CKD. This present work represents a sub-study of the LORD trial, which aimed to determine the effects of atorvastatin on arterial stiffness (aortic PWV and AIx) and central blood pressure in patients with stage 2 − 4 CKD.
Methods

Study Design
The LORD study protocol has been published 18) and was conducted at the Launceston General Hospital and Burnie Renal Units in Northern Tasmania, which service a population of 250,000. The LORD trial adhered to the Declaration of Helsinki and enrolled 132 patients. The Tasmanian Statewide Scientific and Ethics Committees approved the study protocol and all patients provided written informed consent. The trial length of three years was determined based on prior clinical trials assessing the progression of renal disease 19, 20) . The arterial stiffness substudy that enrolled 37 patients commenced in 2004 because the equipment required was not available in our research facility at the start of the LORD trial.
Patients
CKD patients presenting at renal clinics were screened between March 2004 and January 2005 and were eligible at all levels of serum cholesterol and proteinuria. Other inclusion criteria were age between 18 and 85 years, and serum creatinine 1.36 mg/dL. Patients were excluded if they were receiving any form of lipid-lowering therapy and, if female, of childbearing age, able to conceive and not using contraception. Other exclusion criteria were acute liver disease, persistent elevation of transaminases, a history of alcoholism, a seizure within a year of screening, hypersensitivity to atorvastatin, or participation in another clinical investigational drug study within 30 days of screening.
Treatment
Eligible patients were randomly assigned to receive atorvastatin 10 mg or a placebo daily for three years after stratification for disease type. Three stratification groups were used: glomerulonephritis, diabetic nephropathy and other diseases. A clinical research pharmacist, independent of the trial, used computergenerated random numbers placed in blocks of ten per stratification group to conduct the randomisation. At the patient's next scheduled clinic visit, three months later, baseline measures were obtained and the study medication was commenced. Clinical trial coordinators and clinicians, who were blinded to the randomisation assignments, conducted arterial stiffness measures at nine-monthly intervals.
During the study there were no restrictions on the use of blood pressure-lowering therapies and in all patients we aimed to achieve the best possible blood pressure control. The use of any other lipid-lowering therapy was not allowed during the study.
Arterial Stiffness Measures
A central (ascending aortic) pressure waveform was derived by radial tonometry (SPT-301 Mikro-Tip; Millar Instruments, Houston, Texas) using the SphymoCor TM System (AtCor Medical, Sydney, Australia) as previously described 21) . This method involved placing a tonometer over the radial artery and using a generalised transfer function to transform the radial pressure waveform. Central pulse pressure was recorded as an estimate of afterload and AIx as a composite measure of systemic arterial stiffness and arterial wave reflection. The central waveform was calibrated by the average of two measures of brachial blood pressure using a semi-automated device (UA-767, A&D, Saitama, Japan). Aortic stiffness (carotid to femoral PWV) was derived by electrocardiography-gated sequential applanation tonometry using the foot-tofoot method as previously described 21) . For all assessments, patients were instructed to be in the fasting state, including withholding blood pressure therapy, and to have not smoked for the previous 12 hours. Measures were performed after a minimum of five minutes of supine rest.
Statistical Analysis
Aortic PWV was used for sample size calculation. Assuming baseline PWV would be 8.0 1.5 m/s and that an effect size of 1.2 would be clinically significant, with alpha 0.05 and beta (1 − 0.2 0.8), it was calculated that we would require 12 patients per group. As we estimated that 40% of patients would withdraw, we aimed to recruit 40 patients.
All baseline continuous variables were compared between placebo and atorvastatin groups using general linear modelling. Gender and use of medication were compared using exact logistic regression and Fisher's exact test. The time in years between starting the trial medication and the final assessment was calculated for each patient. Comparison of the mean rate of change in blood pressures, PWV and AIx between groups was by general linear modelling. The effects of potential confounding variables (e.g. mean arterial pressure, heart rate, CKD stage and cause, and use of angiotensin converting enzyme inhibitor or angiotensin receptor blocker) were examined by multivariate general linear modelling. Inclusion of drug treatments in the models was determined by forward stepwise regression from a list of drug groups (ACE inhibitors types 1 & 2, calcium antagonists, vasodilators, betablockers, diuretics, nitrates, antacids, calcium, magnesium, digoxin, aspirin, anti-depressants and benzodiazepines), in addition to age, SBP and heart rate. Mean differences, 95% confidence intervals and p-values were corrected for repeated measures, and p-values corrected for multiple comparisons by the Holm method. All analyses were performed using Stata/IC 10.0 for Windows (StataCorp LP, College Station, Tx).
Results
We recruited 37 patients into the sub-study with 19 patients allocated to receive atorvastatin and 18 to receive a placebo; however, three of these patients, all of whom had been assigned to receive atorvastatin, withdrew before starting the study medication or completing the baseline visit. The 34 remaining patients all had two or more evaluations, enabling estimation of the rates of change, except for five patients in the placebo group in whom it was not technically possible to obtain reliable PWV measurements. This was primarily due to excess adiposity and an inability to palpate the femoral artery.
The baseline characteristics of the patients were similar in each group (Table 1, 2) ; however, patients treated with atorvastatin were more likely to be taking an angiotensin converting enzyme inhibitor or angiotensin receptor blocker (atorvastatin 14 of 16, placebo 9 of 18; OR 7.0; 95% CI 1.19 to 41; p 0.031). There were no differences in other antihypertensive therapies, such as calcium channel or beta-blockers, between groups. Two patients in the placebo-treated group and none in the atorvastatin-treated group were receiving an erythropoietic-stimulating agent (p 0.48). The mean age of patients entering the study was 64.1 years. Unexpectedly, no patients were recruited with diabetic nephropathy. The mean length of follow-up was 2.5 years (SD 0.81 yrs). Table 3 and Fig. 1 demonstrate that PWV increased slowly over time in both groups (placebo baseline PWV 8.2 m/sec with a 0.51 m/sec/year increase, p 0.05; atorvastatin baseline PWV 8.3 m/sec with a 0.30 m/sec/year increase, p 0.10). This represented a 41% slower increase in PWV in atorvastatin-treated compared to placebo-treated patients, but this difference was not statistically significant (effect size 0.21, p 0.48). There were no significant differences in the rates of change of systolic, diastolic or pulse pressures (central or peripheral) or AIx during the study ( Table 3) . The results for aortic PWV were not altered after adjustment for mean arterial pressure, heart rate, CKD stage or medication. There were also no group differences in the rates of change of these variables. Significant reductions were seen in serum total (p 0.007) and LDL (p 0.001) cholesterol in atorvastatin-treated patients compared with placebotreated patients ( Table 4 ). There were no significant changes in HDL cholesterol and triglyceride levels between groups. In addition, there were no associations between serum lipid levels and measures of arterial stiffness or blood pressures (data not shown). The findings were not altered by adjustment for CKD stage or cause or the intake of an angiotensin converting enzyme inhibitor or angiotensin receptor blocker. There were no differences in the use of other antihypertensive therapies, such as calcium channel blockers and beta-blockers between groups over the duration of the study. No side effects or adverse events reported with atorvastatin use during the study.
There were no differences in the rate of eGFR 
Discussion
This study is the first long-term randomised controlled trial assessing the effect of a statin on arterial stiffness in patients with CKD. Although there were no statistically significant differences in the rates of change of aortic PWV between atorvastatin-treated and placebo-treated groups, there was a significant increase in aortic PWV over the duration of the trial in placebo-treated patients that was not seen in atorvastatin-treated patients. The clinical significance of aortic PWV attenuation by atorvastatin remains to be established.
No long-term studies have assessed the effects of statin therapy on arterial characteristics in CKD patients. In a six-week intervention study, Dogra et al. 17) assessed arterial compliance in patients with advanced stages of CKD. In this study they found that SBP systolic blood pressure, DBP diastolic blood pressure, PP pulse pressure, BP blood pressure, AIx augmentation index, PWV pulse wave velocity atorvastatin-treated patients improved small artery stiffness. Other studies have assessed the effect of statins on arterial stiffness but these were in other disease states and in patients with normal kidney function [13] [14] [15] [16] 22) . Our findings of a slower increase in arterial stiffness in atorvastatin-treated patients are compatible with those reported in clinical contexts.
Our results showed an increase in regional arterial stiffness over the duration of the study in placebotreated patients but not atorvastatin-treated patients. Over this time, there were no differences in kidney function changes between atorvastatin and placebotreated patients that could have contributed to this difference. There was, however, a reduction in serum total and LDL cholesterol in atorvastatin treated patients. Importantly, there were no blood pressure differences that might have accounted for the PWV changes, suggesting that atorvastatin may have had a direct affect on large central artery structural characteristics. AIx is a marker of systemic arterial stiffness, whereas aortic PWV is a regional stiffness measure that may respond differentially to the aging process 23) or medication 24) . Thus, there is no expectation that both indices should follow the same pattern of change in response to atorvastatin.
There are several limitations to the findings of our study. Firstly, although the sample size was relatively small, it met the requirements based on our sample size calculation. Even so, a recent study reported by Frimodt-Moller et al. 25) in a sample of 19 patients with CKD found good reproducibility with the PWV technique, indicating that a small sample size could yield significant results. Secondly, the baseline PWV was lower in the CKD patients in our study at 8 m/sec than in other CKD cohorts with 10.1 m/sec in stage 3 − 4 CKD 9; however, the observed aortic PWV was similar to that used in our sample size calculation. This lower PWV at the baseline in our study, compared with others, may have been due to the absence of diabetics, who are known to have increased aortic PWV 26) . Thirdly, the 10 mg dose of atorvastatin chosen for the LORD trial was considered adequate when the study was designed but this would now be considered low. There was, however, a significant decrease in Regression lines were derived from repeated measures analysis.
serum total (11.5%) and LDL cholesterol (34.9%) levels during the study. Despite this effect on lipids, there was no significant effect on kidney function. A larger dose of atorvastatin may have been more effective based on recent post-hoc analysis of the Treating to New Targets trial where 80 mg atorvastatin was more effective to preserve kidney function than 20 mg in patients with cardiovascular disease 27) . In conclusion, arterial stiffness measured by aortic PWV showed a significant increase over time in placebo-treated patients but not in atorvastatin-treated patients; however there were no statistically significant differences between the rates of change of aortic PWV between groups. Thus, atorvastatin may attenuate the increase in arterial stiffness in non-diabetic CKD patients not taking lipid-lowering therapy at trial entry. Further studies on other CKD populations, including diabetics, using larger statin doses are required. 
